Comprehensive Prospective Comparison Of Two Robotic Platforms In Anatomical Lung Resections: Clinical Outcomes And Cost-utility Analysis

Condition(s) studied

Investigational drug(s) / intervention(s)

da Vinci Xi Surgical System: Robotic platform used to perform anatomical lung resection (lobectomy or segmentectomy)

Versius Surgical System: Robotic platform used to perform anatomical lung resection (lobectomy or segmentectomy)

Study summary

The goal is to compare clinical outcomes, hospital costs, and cost-utility in patients undergoing anatomical lung resections with DaVinci Xi vs Versius platforms

The main questions it aims to answer are:

* Do patients that undergo an anatomical lung resection with DaVinci Xi have the same clinical outcomes (complications, stay...) than those who were operated with Versius?
* Are anatomical lung resections performed with DaVinci Xi more expensive than those performed with Versius?
* Are anatomical lung resection performed with DaVinci Xi more cost-effective than those performed with Versius?

Participants already undergoing robotic anatomical lung resection as part of their regular medical care will answer quality of life questionnaires preoperatively, at 1, 3, 6, and 12 months after surgery.

Eligibility

Primary outcome measure(s)

• Cost/utility ratio — Data will be collected preoperatively (baseline), at 1, 3, 6, and 12 months after surgery.
  The cost/utility ratio will be calculated as the incremental cost per quality-adjusted life year (QALY) gained, comparing robotic-assisted thoracic surgery (RATS) with Da Vinci Xi and Versius. Costs will include all direct procedural costs (including consumables, reusable instruments, operating room time, and maintenance costs of equipment), as well as postoperative hospital-related costs. Health outcomes will be expressed in QALYs, derived from validated health-related quality of life measures collected during follow-up. The analysis will be conducted from the healthcare system perspective, and results will be expressed as an incremental cost-effectiveness ratio (ICER).\*

Trial sites (1)

More Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal trials in Spain

Other trials for the same condition